Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.4% Today

What is Intellia Therapeutics, Inc.?

NTLA, or Intellia Therapeutics Inc., is a biotechnology company focused on developing CRISPR/Cas9 gene editing therapies. The overall market sentiment today was positive with a bullish trend.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 5.4% on Aug 22, 2025 14:16

• NTLA experienced a strong bullish movement possibly due to positive developments in the biotechnology sector.
• Cathie Wood's Ark Invest selling off shares of Robinhood and Shopify may have redirected investor interest towards other innovative companies like Intellia Therapeutics.
• The hype surrounding AI launches could have also contributed to increased investor confidence in NTLA's gene editing technologies.
• Overall, the bullish movement in NTLA could be a result of shifting investor focus towards promising biotech companies amidst market uncertainties.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Cathie Wood's Ark Dumps $1.6 Million In Robinhood Stock Amid AI Launch Hype, Dumps Shopify Stock As Well - ARK Fintech Innovation ETF ( BATS:ARKF ) , Robinhood Markets ( NASDAQ:HOOD )

On Thursday, Cathie Wood-led Ark Invest executed significant trades involving Shopify Inc. SHOP and Robinhood Markets Inc. HOOD. Ark Invest, through its Ark Fintech Innovation ETF ARKF, sold 14,914 shares of Robinhood. With the stock closing at $106.30, this transaction was valued at ...

https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/08/47273695/cathie-woods-ark-dumps-1-6-million-in-robinhood-stock-amid-ai-launch-hype-dumps-shopif

Trending Today

Aave ($AAVE) Crypto Forecast: Down 5.2% Today

Ondo ($ONDO) Crypto Forecast: Down 5.3% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

Affirm Holdings Inc. ($AFRM) Stock Forecast: Up 5.2% Today

Illumina Inc. ($ILMN) Stock Forecast: Up 5.2% Today

Tilray Inc. ($TLRY) Stock Forecast: Up 5.3% Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Up 5.1% Today

Duolingo Inc. ($DUOL) Stock Forecast: Down 5.0% Today

Teleflex Incorporated ($TFX) Stock Forecast: Down 5.1% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Down 8.1% Today

Intellia Therapeutics, Inc. Price History

30.04.2025 - NTLA Stock was down 5.8%

• NTLA stock saw a notable decrease following reports of an individual experiencing adverse effects in its gene therapy trial, particularly linked to elevated liver enzymes.
• The downward trend in the stock could be connected to worries regarding the safety and effectiveness of Intellia's gene therapy contender, nex-z, for addressing ATTR-CM.
• Investors might be responding to the possible setbacks in Intellia's phase III trial, causing a loss of faith in the company's future role in the gene therapy industry.
• This incident underscores the risks and fluctuations inherent in biotech stocks, where the outcomes of clinical trials can profoundly influence stock performance.

16.04.2025 - NTLA Stock was up 5.4%

• The FDA approval for Incyte's drug Zynyz in a new cancer indication may have positively influenced the overall sentiment in the biotechnology sector, which includes companies like Intellia Therapeutics.
• Optimistic projections from Wall Street analysts indicating a significant upside in NTLA stock likely played a role in the bullish movement, with investors responding to growth potential.
• Positive industry developments and favorable analyst forecasts may have boosted investor confidence in Intellia Therapeutics, contributing to the strong bullish movement in the stock.

08.07.2025 - NTLA Stock was down 5.1%

• NTLA reported a narrower Q2 loss and exceeded revenue predictions, yet the stock faced a bearish movement.
• The market's negative response could stem from apprehensions regarding the company's future growth or guidance.
• Investors might be selling to secure profits after a recent stock price surge driven by encouraging pipeline updates.
• Despite the earnings beat and advancements in phase III studies for ATTR and HAE programs, broader market conditions or sector shifts may be casting a shadow.

21.04.2025 - NTLA Stock was down 5.1%

• The decline in Intellia Therapeutics (NTLA) could be due to investors taking profits following a period of strong performance.
• Investor attention may have shifted to other biotech companies after FDA approval was granted for Zynyz in a new cancer indication for Incyte, prompting a sell-off in NTLA.
• High price targets set by Wall Street analysts, predicting a 408.6% increase in NTLA, might have raised concerns about the stock being overvalued, leading some investors to sell their shares.
• The bearish trend in NTLA appears to stem from a mix of profit-taking, changing investor focus, and potential worries about the stock's valuation based on analyst forecasts.

01.07.2025 - NTLA Stock was down 5.1%

• The bearish movement in NTLA stock may be linked to an investigation alert by Bragar Eagel & Squire, P.C., raising investor concerns and leading to selling pressure.
• The market sentiment may have been negatively impacted by inducement grants reported by Intellia Therapeutics, as investors may have reservations about their effects on the company's financials.
• An upcoming conference call to discuss second-quarter earnings and company updates could have created uncertainty among investors, prompting a more cautious approach towards the stock.
• Despite the positive outlook for genomics stocks overall, recent news related to Intellia Therapeutics appears to have dampened industry prospects, resulting in the bearish movement of NTLA stock.

08.06.2025 - NTLA Stock was up 5.8%

• Stock of Intellia Therapeutics has risen by 29.8% over the previous month, propelled by advancements in its gene therapy pipeline and growing investor attention.
• The recent FDA approval of Ekterly by KalVista Pharmaceuticals, the first oral on-demand treatment for HAE, is believed to have positively impacted confidence in the biotech sector, which includes NTLA.
• Encouraging updates on gene therapy progress and FDA approvals within the biotech industry may have influenced the strong bullish movement in NTLA today.
• Investors seem to be hopeful about the potential expansion and innovation in the gene editing and biopharmaceutical industries, resulting in heightened buying interest for companies like Intellia Therapeutics.

29.04.2025 - NTLA Stock was down 23.7%

• The investigation may have raised concerns among investors about potential legal issues or regulatory challenges for Intellia Therapeutics.
• The uncertainty surrounding the investigation could have led to a loss of confidence in the company's future prospects, resulting in a bearish movement in NTLA stock.
• Investors may be closely monitoring any developments related to the investigation and awaiting further clarity before making investment decisions in Intellia Therapeutics.

05.05.2025 - NTLA Stock was down 5.1%

• Beam Therapeutics' gene-editing therapy for sickle cell disease gaining orphan drug status from the FDA resulted in a surge in BEAM stock.
• Despite Wall Street analysts projecting a potential 398.3% upside for Intellia Therapeutics, the stock still experienced a bearish movement.
• Intellia's stock decline could be linked to a patient in its phase III study encountering adverse events, which impacted the company's gene therapy candidate and investor sentiment.
• The gene-editing sector's competition, notably with CRISPR advancing its in vivo pipeline, contributes to the intricate market dynamics affecting Intellia's stock performance.

27.05.2025 - NTLA Stock was up 6.5%

• NTLA's positive developments in its CRISPR/Cas9-based therapies could be driving its bullish movement, indicating progress in its pipeline.
• Investor interest in NTLA may have been sparked by comparisons with CRISPR Therapeutics (CRSP), leading to the uptick in the market.
• The advancements in gene editing technology by NTLA are seen as promising by investors, contributing to the increase in stock price.
• NTLA may have responded to a perceived edge by CRISPR Therapeutics (CRSP) by highlighting its own potential, resulting in the bullish market movement.

22.07.2025 - NTLA Stock was up 5.4%

• NTLA experienced a strong bullish movement possibly due to positive developments in the biotechnology sector.
• Cathie Wood's Ark Invest selling off shares of Robinhood and Shopify may have redirected investor interest towards other innovative companies like Intellia Therapeutics.
• The hype surrounding AI launches could have also contributed to increased investor confidence in NTLA's gene editing technologies.
• Overall, the bullish movement in NTLA could be a result of shifting investor focus towards promising biotech companies amidst market uncertainties.

19.07.2025 - NTLA Stock was down 6.4%

• The decline in NTLA's stock today could be attributed to investors taking profits following a period of strong growth.
• While news of CRISPR Therapeutics' increasing Casgevy sales was well-received, investors might have been underwhelmed by NTLA's financial performance or future prospects.
• Market fluctuations and sector shifts may have also influenced NTLA's stock decline, as investors may be seeking out other appealing opportunities within the biotech industry.

31.06.2025 - NTLA Stock was down 5.6%

• The bearish movement in NTLA stock today might be attributed to the following reasons:
• Investors may have had high expectations for the second quarter earnings call, leading to disappointment if the results did not meet projections.
• There could be concerns about the company's operational highlights discussed during the call, potentially indicating challenges or setbacks in their CRISPR-based therapies.
• The broader market sentiment towards genomics stocks might have shifted, impacting NTLA along with other companies in the sector.